title: Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medulla.
abstract: The present sutdy aimed to determine whether olmesartan, an angiotensin II (Ang II) type 1 (AT(1)) receptor blocker, can influence the CA release from the isolated perfused model of the rat adrenal medulla. Olmesartan (5~50 µM) perfused into an adrenal vein for 90 min produced dose- and time-dependent inhibition of the CA secretory responses evoked by ACh (5.32 mM), high K(+) (56 mM, a direct membrane-depolarizer), DMPP (100 µM) and McN-A-343 (100 µM). Olmesartan did not affect basal CA secretion. Also, in adrenal glands loaded with olmesartan (15 µM), the CA secretory responses evoked by Bay-K-8644 (10 µM, an activator of voltage-dependent L-type Ca(2+) channels), cyclopiazonic acid (10 µM, an inhibitor of cytoplasmic Ca(2+) -ATPase), veratridine (100 µM, an activator of voltage-dependent Na(+) channels), and Ang II (100 nM) were markedly inhibited. However, at high concentrations (150~300 µM), olmesartan rather enhanced the ACh-evoked CA secretion. Taken together, these results show that olmesartan at low concentrations inhibits the CA secretion evoked by cholinergic stimulation (both nicotininc and muscarinic receptors) as well as by direct membrane depolarization from the rat adrenal medulla, but at high concentrations it rather potentiates the ACh-evoked CA secretion. It seems that olmesartan has a dual action, acting as both agonist and antagonist at nicotinic receptors of the isolated perfused rat adrenal medulla, which might be dependent on the concentration. It is also thought that this inhibitory effect of olmesartan may be mediated by blocking the influx of both Na(+) and Ca(2+) into the rat adrenomedullary chromaffin cells as well as by inhibiting the Ca(2+) release from the cytoplasmic calcium store, which is thought to be relevant to the AT(1) receptor blockade, in addition to its enhancement on the CA secreton.
authors.affiliation: Department of Internal Medicine, School of Medicine, Seoul National University, Seoul 710-744, Korea.
authors.forename: Hyo-Jeong
authors.initials: HJ
authors.lastname: Lim
authors.forename: Sang-Yong
authors.initials: SY
authors.lastname: Kim
authors.forename: Dong-Yoon
authors.initials: DY
authors.lastname: Lim
references.citation: Neuron. 2000 Apr;26(1):13-25
references.pmid: 10798388
references.citation: Nature. 1984 May 3-9;309(5963):69-71
references.pmid: 6201747
references.citation: Eur J Pharmacol. 1995 Oct 16;285(2):181-8
references.pmid: 8566137
references.citation: Life Sci. 1982 Dec 27;31(26):2991-8
references.pmid: 6897666
references.citation: Regul Pept. 1993 Jan 22;43(1-2):1-20
references.pmid: 8426906
references.citation: Am J Hypertens. 2005 Feb;18(2 Pt 1):287-94
references.pmid: 15752958
references.citation: Hypertension. 1998 Jan;31(1 Pt 2):384-90
references.pmid: 9453333
references.citation: Brain Res Bull. 1995;38(5):441-6
references.pmid: 8665267
references.citation: FEBS Lett. 1989 Apr 24;247(2):429-34
references.pmid: 2653866
references.citation: Eur J Pharmacol. 2004 Apr 5;489(1-2):67-75
references.pmid: 15063157
references.citation: Biochem Pharmacol. 1989 Nov 15;38(22):3995-4003
references.pmid: 2532015
references.citation: Basic Res Cardiol. 1998;93 Suppl 2:24-9
references.pmid: 9833158
references.citation: Circulation. 2001 Feb 13;103(6):904-12
references.pmid: 11171802
references.citation: J Anat. 1993 Oct;183 ( Pt 2):277-89
references.pmid: 7507911
references.citation: Annu Rev Physiol. 1995;57:521-46
references.pmid: 7778876
references.citation: Kidney Int. 2000 Jun;57(6):2457-67
references.pmid: 10844614
references.citation: J Neurochem. 1986 Feb;46(2):637-40
references.pmid: 3484517
references.citation: J Pharmacol Exp Ther. 1962 Dec;138:360-75
references.pmid: 14013351
references.citation: J Neurochem. 1991 Mar;56(3):1083-6
references.pmid: 1993889
references.citation: Neuroscience. 1985 May;15(1):283-92
references.pmid: 2409474
references.citation: Blood Press Suppl. 1994;5:105-8
references.pmid: 7889190
references.citation: J Renin Angiotensin Aldosterone Syst. 2004 Jun;5(2):93-6
references.pmid: 15295722
references.citation: Am J Hypertens. 2002 Oct;15(10 Pt 2):108S-114S
references.pmid: 12383591
references.citation: J Neurosci. 2000 Jul 1;20(13):4776-85
references.pmid: 10864935
references.citation: Endocrinology. 2001 Jul;142(7):3075-86
references.pmid: 11416030
references.citation: N Engl J Med. 1996 Jun 20;334(25):1649-54
references.pmid: 8628362
references.citation: Brain Res. 2004 Nov 26;1028(1):9-18
references.pmid: 15518636
references.citation: Can J Physiol Pharmacol. 1999 May;77(5):367-74
references.pmid: 10535686
references.citation: J Cardiovasc Pharmacol. 2005 Nov;46(5):585-93
references.pmid: 16220064
references.citation: Regul Pept. 1985 Nov 28;12(4):263-72
references.pmid: 3003818
references.citation: Science. 1995 Apr 14;268(5208):239-47
references.pmid: 7716515
references.citation: J Biol Chem. 1989 Oct 25;264(30):17816-23
references.pmid: 2530215
references.citation: J Neurochem. 1982 Sep;39(3):635-46
references.pmid: 7097273
references.citation: Br J Pharmacol. 2007 Aug;151(7):952-62
references.pmid: 17572702
references.citation: Yakugaku Zasshi. 2005 Aug;125(8):653-7
references.pmid: 16079616
references.citation: J Biol Chem. 1983 Apr 25;258(8):4989-93
references.pmid: 6833287
references.citation: Br J Pharmacol. 1992 Sep;107(1):134-40
references.pmid: 1330156
references.citation: J Pharmacol Exp Ther. 1990 Nov;255(2):584-92
references.pmid: 2243344
references.citation: Science. 1978 Dec 8;202(4372):1091-3
references.pmid: 152460
references.citation: Int J Clin Pharmacol Res. 2005;25(1):41-6
references.pmid: 15864875
references.citation: Endocrinology. 2001 Sep;142(9):3880-9
references.pmid: 11517166
references.citation: Biol Signals. 1993 May-Jun;2(3):166-72
references.pmid: 8004155
references.citation: J Physiol. 1981;313:463-80
references.pmid: 7277230